1 month ago
35
MarketBeat
Tue, April 21, 2026 astatine 10:51 AM CDT 8 min read
-
Danaher reported Q1 income of $6.0 billion with halfway gross up 0.5% year-over-year, adjusted EPS of $2.06 (up 9.5%), improved margins (gross 60.3%, adjusted operating 30.2%), $1.1 cardinal escaped currency flow, and raised its full-year adjusted EPS usher to $8.35–$8.55 portion keeping halfway gross guidance astatine 3%–6%.
-
Segment trends were mixed: bioprocessing grew precocious azygous digits with instrumentality orders up >30%—an aboriginal motion of a imaginable multi-year concern cycle—while diagnostics were pressured by a ~25% diminution successful Cepheid respiratory gross and China pricing headwinds from volume-based procurement.
-
Management reiterated the planned Masimo acquisition, forecasting ~$125 cardinal of outgo synergies and ~$50 cardinal of gross synergies by twelvemonth five, expecting the woody to beryllium accretive to adjusted EPS successful the archetypal afloat twelvemonth and to effect successful astir 2.5x nett leverage post-close with leverage to diminution rapidly fixed expected >$5 cardinal yearly escaped currency flow.
-
Interested successful Danaher Corporation? Here are 5 stocks we similar better.
-
The Often-Missed Corner of Healthcare That Wall Street Is Loving
Danaher (NYSE:DHR) reported first-quarter 2026 income of $6.0 billion, with halfway gross up 0.5% twelvemonth implicit twelvemonth arsenic spot successful bioprocessing and better-than-expected beingness sciences show mostly offset a lighter-than-normal respiratory play astatine Cepheid. President and CEO Rainer Blair said the institution delivered “better than expected adjusted EPS growth” by “leveraging the Danaher Business System to accelerate innovation, thrust productivity gains, and deliver” operating improvements successful a “dynamic environment.”
Blair said the 4th featured a 2.5% headwind from respiratory revenue, portion the remainder of the portfolio grew 3% connected a halfway basis. He added that respective extremity markets were “modestly amended than our expectations entering the year,” citing robust commercialized monoclonal antibody accumulation and gradual betterment successful R&D spending astatine ample pharma and biopharma. Smaller biotech and academic/government customers were described arsenic unchangeable sequentially, with “some pockets of improved bid and funnel activity.”
→ $39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent Inflation
-
An AI Play Hiding successful Plain Sight: A Look astatine Johnson Controls
On profitability, Danaher reported gross nett borderline of 60.3% and adjusted operating nett borderline of 30.2%, up 60 ground points, which Blair attributed to year-over-year outgo savings that much than offset the interaction of little respiratory revenue. Adjusted diluted net per stock were $2.06, up 9.5% twelvemonth implicit year. Free currency travel was $1.1 billion, with a free-cash-flow-to-net-income conversion ratio of 105%.
English (CA) · 
English (US) · 
Spanish (MX) ·